Single Cell Acute Leukemia Analysis (SCALA)

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Not yet enrolling

Conditions: Acute Myeloid Leucemia

Treatments: Procedure: blood sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT06906978

2025-A00734-45. (Other Identifier)

RCAPHM25_0039

Details and patient eligibility

About

Numerous chemotherapy and immunotherapy resistance genes have been identified in cancers in general and acute myeloid leukemia in particular. As a preliminary to this study, the investigators hypothesized the co-expression of these genes in the same cell as a major factor in relapse. This hypothesis was supported in vitro by the study of the evolution of these co-expressions after incubation with chemotherapy drugs. The current study aims to verify this hypothesis by studying the expression of these genes in single-cell samples from relapsed acute myeloid leukemia patients.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient
• Patient who has received information about the study and has not expressed opposition,
• Patients who are beneficiaries of a social security plan,
• Patient with relapsed or refractory acute myeloid leukemia, whatever the previous treatment, the therapeutic line and the time between the previous treatment and the relapse.

Exclusion criteria

• Persons who do not understand the French language if there is no translator available to translate for them.
• Absence of circulating blastosis.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Patient with acute myeloid leukemia

Other group

Description:

Adult patient with acute myeloid for whom an additionnal 20 mL of blood will be collected.

Treatment:

Procedure: blood sampling